Clinical Trial Update: A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis [Phase 3]

View source ↗

Summary

Long-term Phase 3 study assessing the safety and efficacy of baricitinib (LY3009104) for atopic dermatitis. The trial has completed and results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-07-01